Chondrokalzinose und Pseudogicht – aktueller denn je

Zusammenfassung

Mit steigender Lebenserwartung ist eine steigende Prävalenz von kristallinduzierten Arthritiden zu beobachten. Für die Gicht gilt das ebenso wie für die Kalziumpyrophosphat-Dihydrat (CPPD)-Ablagerungskrankheit, die sich als akute Arthritis oder unter dem klinischen Bild zunehmender Schübe aktivierter Arthrosen zeigen kann. Die Diagnose ist durch typische Knorpelverkalkungen (Chondrokalzinose) oder durch den Nachweis von Pyrophosphatkristallen aus dem Gelenk zu stellen. Trotz neuer Daten zur Pathogenese existieren bisher keine kausalen Therapieansätze. Die Klärung sekundärer Formen, wie Hyperparathyreoidismus und Hämochromatose, ist daher besonders relevant. In der folgenden Übersichtsarbeit soll der aktuelle Wissensstand zu Pathogenese, Diagnostik und Therapie dargestellt werden.

Abstract

As life expectancy increases, a rise in the prevalence of crystal arthropathies can be observed. This is true for gout as well as for the calcium pyrophosphate dihydrate (CPPD) deposition disease, which clinically appears as acute arthritis or with increasing flares resembling activated osteoarthritis. Diagnosis relies on typical calcifications of cartilage (chondrocalcinosis) or the detection of pyrophosphate crystals in joint material. Although there have been new findings that consider the pathogenesis, there is still no causal therapy in sight. Therefore it is important to search for potential causes of secondary forms, such as hyperparathyroidism and haemochromatosis. The present review summarises current knowledge on the pathogenesis, diagnosis and therapeutic options.

Chondrokalzinose - Pseudogicht - Kristallarthropathie - akute Arthritis

chondrocalcinosis - pseudogout - crystal arthropathies - acute arthritis

Literatur

• 1 Agudelo C A, Wise C M. Crystal-associated arthritis.  Clin Geriatr Med. 1998;  14 (3) 495-513
• 2 Announ N, Guerne P A. Diagnosis and treatment of calcium pyrophosphate crystal-induced arthropathy.  Z Rheumatol. 2007;  66 (7) 573-578
• 3 Aouba A, Vuillemin-Bodaghi V, Mutschler C. et al . Crowned dens syndrome misdiagnosed as polymyalgia rheumatica, giant cell arteritis, meningitis or spondylitis: an analysis of eight cases.  Rheumatology. 2004;  43 (12) 1508-1512
• 4 Bruges-Armas J, Couto A R, Timms A. et al . Ectopic calcification among families in the Azores: clinical and radiologic manifestations in families with diffuse idiopathic skeletal hyperostosis and chondrocalcinosis.  Arthritis Rheum. 2006;  54 (4) 1340-1349
• 5 Cailotto F, Bianchi A, Sebillaud S. et al . Inorganic pyrophosphate generation by transforming growth factor-beta-1 is mainly dependent on ANK induction by Ras/Raf-1 /extracellular signal-regulated kinase pathways in chondrocytes.  Arthritis Res Ther. 2007;  9 (6) R122
• 6 Calò L, Punzi L, Semplicini A. Hypomagnesemia and chondrocalcinosis in Bartter’s and Gitelman’s syndrome: review of the pathogenetic mechanisms.  Am J Nephrol. 2000;  20 (5) 347-350
• 7 Chollet-Janin A, Finckh A, Dudler J. et al . Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis.  Arthritis Rheum. 2007;  56 (2) 688-692
• 8 Choy G. An update on the treatment options for gout and calcium pyrophosphate deposition.  Expert Opin Pharmacother. 2005;  6 (14) 2443-2453
• 9 Costello J C, Ryan L M. Modulation of chondrocyte production of extracellular inorganic pyrophosphate.  Curr Opin Rheumatol. 2004;  16 (3) 268-272
• 10 Couto A R, Brown M A. Genetic factors in the pathogenesis of CPPD crystal deposition disease.  Curr Rheumatol Rep. 2007;  9 (3) 231-236
• 11 Dalbeth N, Haskard D O. Inflammation and tissue damage in crystal deposition diseases.  Curr Opin Rheumatol. 2005;  17 (3) 314-318
• 12 Ea H K, Blanchard A, Dougados M. et al . Chondrocalcinosis secondary to hypomagnesemia in Gitelman’s syndrome.  J Rheumatol. 2005;  32 (9) 1840-1842
• 13 Fenoy A J, Menezes A H, Donovan K A. et al . Calcium pyrophosphate dihydrate crystal deposition in the craniovertebral junction.  J Neurosurg Spine. 2008;  8 (1) 22-29
• 14 Filippou G, Frediani B, Gallo A. et al . A „new” technique for the diagnosis of chondrocalcinosis of the knee: sensitivity and specificity of high-frequency ultrasonography.  Ann Rheum Dis. 2007;  66 (8) 1126-1128
• 15 Ho A M, Johnson M D, Kingsley D M. Role of the mouse ank gene in control of tissue calcification and arthritis.  Science. 2000;  289 (5477) 265-270
• 16 Jones A C, Chuck A J, Arie E A. et al . Diseases associated with calcium pyrophosphate deposition disease.  Semin Arthritis Rheum. 1992;  22 (3) 188-202
• 17 Kohn N N, Hughes R E, McCarty D J. et al . The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: the „pseudogout syndrome”. II. Identification of crystals.  Ann Intern Med. 1962;  56 738-745
• 18 Langwieser Jr G, Müller K. Die Chondrocalcinose: eine Ursache akuter Verwirrtheitszustände.  Geriatrie Praxis. 2003;  1 39-42
• 19 Martinon F, Pétrilli V, Mayor A. et al . Gout-associated uric acid crystals activate the NALP3 inflammasome.  Nature. 2006;  440 (7081) 237-241
• 20 Netter P, Bardin T, Bianchi A. et al . The ANKH gene and familial calcium pyrophosphate dihydrate deposition disease.  Joint Bone Spine. 2004;  71 (5) 365-368
• 21 Neogi T, Nevitt M, Niu J. et al . Lack of association between chondrocalcinosis and increased risk of cartilage loss in knees with osteoarthritis: results of two prospective longitudinal magnetic resonance imaging studies.  Arthritis Rheum. 2006;  54 (6) 1822-1828
• 22 Pego-Reigosa J M, Rodriguez-Rodriguez M, Hurtado-Hernandez Z. et al . Calcium pyrophosphate deposition disease mimicking polymyalgia rheumatica: a prospective followup study of predictive factors for this condition in patients presenting with polymyalgia symptoms.  Arthritis Rheum. 2005;  53 (6) 931-938
• 23 Perez-Ruiz F, Testillano M, Gastaca M A. et al . „Pseudoseptic” pseudogout associated with hypomagnesemia in liver transplant patients.  Transplantation. 2001;  71 (5) 696-698
• 24 Pétrilli V, Dostert C, Muruve D A. et al . The inflammasome: a danger sensing complex triggering innate immunity.  Curr Opin Immunol. 2007;  19 (6) 615-622
• 25 Pytel P, Wollmann R L, Fessler R G. et al . Degenerative spine disease: pathologic findings in 985 surgical specimens.  Am J Clin Pathol. 2006;  125 (2) 193-202
• 26 Richette P, Ayoub G, Lahalle S. et al . Hypomagnesemia associated with chondrocalcinosis: a cross-sectional study.  Arthritis Rheum. 2007;  57 (8) 1496-1501
• 27 Rosenthal A K. Update in calcium deposition diseases.  Curr Opin Rheumatol. 2007;  19 (2) 158-162
• 28 Rothschild B. Suppressive treatment of calcium pyrophosphate deposition disease.  Arthritis Rheum. 2007;  56 (9) 3172
• 29 Salaffi F, De Angelis R, Grassi W. MArche Pain Prevalence INvestigation Group (MAPPING) study. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study.  Clin Exp Rheumatol. 2005;  23 (6) 819-828
• 30 Schneider P, Schneider I. Calcium pyrophosphate dihydrate-crystal induced arthropathy.  Z Rheumatol. 2004;  63 (1) 10-21
• 31 Tausche A K, Unger S, Richter K. et al . Hyperuricemia and gout: diagnosis and therapy.  Internist. 2006;  47 (5) 509-520
• 32 Williams C J, Zhang Y, Timms A. et al . Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH.  Am J Hum Genet. 2002;  71 (4) 985-991
• 33 Winzer M, Grässler J, Aringer M. Crystal-induced arthritis – old but important.  Z Rheumatol. 2007;  66 (4) 317-324
• 34 Zaka R, Williams C J. Role of the progressive ankylosis gene in cartilage mineralization.  Curr Opin Rheumatol. 2006;  18 (2) 181-186
• 35 Zhang W, Neame R, Doherty S. et al . Relative risk of knee chondrocalcinosis in siblings of index cases with pyrophosphate arthropathy.  Ann Rheum Dis. 2004;  63 (8) 969-973
• 36 Zhang Y, Johnson K, Russell R G. et al . Association of sporadic chondrocalcinosis with a –4-basepair G-to-A transition in the 5’-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate.  Arthritis Rheum. 2005;  52 (4) 1110-1117
• 37 Zhang Y, Brown M A. Genetic studies of chondrocalcinosis.  Curr Opin Rheumatol. 2005;  17 (3) 330-335
• 38 Zhang Y, Johnson K, Russell R G. et al . Association of sporadic chondrocalcinosis with a –4-basepair G-to-A transition in the 5’-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate.  Arthritis Rheum. 2005;  52 (4) 1110-1117
• 39 Zustin J, Fürst M, Sauter G. et al . Crystal-induced arthropathies.  Z Rheumatol. 2008;  67 (1) 47-50